JMU-N2

About this trial

Last updated 13 years ago

Study ID

JMU-N2

Status

Withdrawn

Type

Interventional

Phase

Phase 4

Placebo

Accepting

65+ Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended 13 years ago

The purpose of this study is to determine whether eplerenone is effective in the treatment of blood pressure, heart function, renal function in elderly hypertensive stage1 (eGFR>=90ml/min/1.73m2) and stage2 (eGFR 60-89ml/min/1.73m2) chronic kidney disease (CKD) patients.

Inclusion Criteria

- Clinical diagnosis of stage1(eGFR>=90ml/min/1.73m2) and stage2 (eGFR 60- 89ml/min/1.73m2)chronic kidney disease

- Clinical diagnosis of Hypertension (Blood pressure >=140/90mmHg)

- Elderly people(>=65 years old)

Exclusion Criteria

- The patients who are already taking eplerenone

- Stage3(eGFR 30-60 ml/min/1.73m2),stage4(eGFR 15-30 ml/min/1.73m2)and stage5 (eGFR <15 ml/min/1.73m2) CKD patients

- The patients who are receiving hemodialysis or peritoneal dialysis

- The patients who are taking itraconazole, ritonavir and nelfinavir

- The patients who are taking potassium-sparing diuretics and potassium supplement

- The patients who have hyperkalemia(>=5.5mEq/ml)

- Severe heart failure (>=NYHA class III)

- Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (>=HbA1c 9.0&)

- Severe liver dysfunction (five folds increased AST or ALT than standard values)

Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients